A new initiative from Opalmedica is placing patient voices at the centre of efforts to improve rare disease diagnosis, with the launch of its innovative KLEOS™ platform.
The platform is designed to tackle one of the most persistent challenges in rare disease care: the long and often complex journey to diagnosis.
For many people, receiving an accurate diagnosis can take years. Symptoms are frequently subtle, varied or misunderstood, making it difficult for healthcare professionals to identify patterns early. KLEOS™ aims to change this by combining clinical expertise with real-world patient data.
At the heart of the platform is a simple but powerful idea, learning from lived experience. Patients are invited to share their diagnostic journeys through an online survey, contributing to a growing dataset that helps identify patterns in symptoms and disease progression. These insights are then used to support GPs during routine consultations, highlighting potential indicators of rare diseases in real time.
“Everyone’s diagnosis journey is unique,” yet collectively these experiences can reveal crucial insights. With around 1 in 17 people affected by a rare disease in their lifetime, the potential impact of earlier detection is significant.
Privacy and trust are central to the initiative. All data shared through KLEOS™ is anonymised and handled in line with data protection regulations, ensuring participants can contribute safely while helping to advance research and understanding.
The platform also empowers patients to play an active role in shaping the future of care. By sharing their stories via My Rare Journey, individuals become part of a wider movement aimed at reducing diagnostic delays and improving outcomes for future patients.
As rare disease communities continue to advocate for faster, more accurate diagnoses, initiatives like KLEOS™ signal a growing recognition that patient insight is not just valuable, but essential.
Share your story here: My Rare Journey | OpalMedica